Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 700-711

  Barras, Michael A ^a,b   Duffull, Stephen B ^c   Atherton, John J ^a,d   Green, Bruce ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e Model Answers Pty Ltd   (Australia)

Author keywords

Anticoagulants; Enoxaparin; Exposure response modelling; Obesity; Renal disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN BRUISING;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; OBESITY; RISK FACTORS; THROMBOEMBOLISM;

EID: 70449333353     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03518.x     Document Type: Article

References (44)

1. Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, Langer A, Califf R, Fox K, Premmereur J, Bigonzi F, Stephens J, Weatherley B. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997 337 : 447 452.
2. Antman EM, McCabe C, Gurfinkel E, Turpie A, Alexander G, Bernink P, Salein D, de Luna A, Fox K, LaBlanche J-M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 100 : 1593 1601.
3. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Candales J, Guneri S, Jiang F, White H, Fox K, Braunwald E. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006 354 : 1477 1488.
4. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA 2004 292 : 45 54.
5. Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, Elias D, Grigg A, Musset D, Rodgers G, Trowbridge A, Yusen R, Zawilska K. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med 2001 134 : 191 202.
6. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight-heparin compared with intravenous heparin for treatment of pulmonary embolism. Ann Intern Med 2004 140 : 175 183.
7. Aroney CN, Aylward P, Kelly A-M, Chew DP, Clune E. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006 184 (Suppl. S1 S32.
8. Buller HR, Agnelli MD, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. Chest 2004 126 (Suppl. 401S 28S.
9. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Bass EB. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the Academy of Family Physicians. Ann Intern Med 2007 146 : 204 210. (Pubitemid 351650634)
10. Lovenox® prescribing information. Available at http://www.sanofi- aventis.us/ (last accessed 6 April 2008).
11. Product information Clexane®. Available at http://www.sanofi-aventis. co.uk/prodcuts/Clexane-spc.pdf (last accessed 6 April 2008).
12. Clexane® product information. Available at http://www.sanofi-aventis. com.au/products/aus-pi-clexane.pdf (last accessed 6 April 2008).
13. Thrombolysis in Myocardial Infarction (TIMI) 11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997 29 : 1474 1482.
14. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2004 59 : 281 290.
15. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003 54 : 96 103.
16. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared to conventional dosing of enoxaparin. Clin Pharmacol Ther 2008 83 : 882 888. (Pubitemid 351704919)
17. Montalescot G, Collet J, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004 110 : 392 398.
18. Cockroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
19. Green B, Duffull SB. Prospective evaluation of a D-Optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn 2003 30 : 145 161.
20. Berkowitz S, Stinnett S, Cohen M, Fromell G, Bigonzi F. Prospective comparison of hemorrhagic complication after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001 88 : 1230 1234.
21. Beal SL, Boeckmann A, Sheiner L. NONMEM User's Guide. Ellicot City, MD : Icon Development Solutions, 1999-2006.
22. Green B, Duffull S. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004 58 : 119 133.
23. Han P, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Phamacol Ther 2007 82 : 505 508.
24. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005 44 : 1051 1065.
25. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001 28 : 481 504.
26. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 2003 30 : 387 404. (Pubitemid 38221931)
27. Ettte EI, Williams P, Kim Y, Lane J, Liu M-J, Capparelli E. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 2003 43 : 610 623.
28. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects populations models. Comput Methods Programs Biomed 1999 59 : 19 29.
29. Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol 2006 62 : 165 176.
30. Hulot J-S, Vantelon C, Urien S, Bouzamondo A. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004 26 : 305 310.
31. Bruno R, Baille P, Retout S, Vivier N. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2002 56 : 407 414.
32. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CMJ, Green B. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008 65 : 964 965.
33. Kim HK, Duffull SB, Green B. The effect of study design on pharmacokinetics in patients with impaired renal function. In: PAGE (2008) Abstr 1354. Available at http://wwwpage-meetingorg/?abstract=1354 (last accessed 8 November 2008).
34. Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Phamacol Ther 2001 69 : 210 222.
35. Moscucci M, Fox KA, Cannon CO, Klein W. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003 24 : 1815 1823. (Pubitemid 37280247)
36. Granger C, Goldberg RJ, Dabbous O, Pieper KS. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003 163 : 2345 2353.
37. Eriksson B, Dahl O, Rosencher N, Kurth A, van Dijk C, Frostick S, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 370 : 949 956. (Pubitemid 47393577)
38. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999 341 : 793 800.
39. Brophy D, Sica D. Use of enoxaparin in patients with chronic kidney disease. Drug Safety 2007 30 : 991 994.
40. Hulot J-S, Montalescot G, Lechat P, Collet J-P, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005 77 : 542 552.
41. Refludan® product information. Available at http://www.drugs.com/pro/ refludan.html (last accessed 26 August 2009).
42. Sanchez-Pena P, Hulot J-S, Urien S, Ankri A, Collet J-P, Choussat R, Lechat P, Montalescot G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 2005 60 : 364 373.
43. Kane-Gill SL, Feng Y, Bobek MB, Pruchnicki MC, Dasta JF. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. J Clin Pharm Ther 2005 30 : 207 213.
44. Berges A, Laporte S, Epinat M, Zufferey P, Tranchand B, Decousus H, Mismetti P. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007 64 : 428 438.